What does Daniel O’Day’s voice even sound like?

That’s among the things many investors will learn Thursday when O’Day, the new CEO at Gilead Sciences, answers questions for the first time since taking the job earlier this year.

As a genre, quarterly earnings calls tend toward the mundane, but O’Day might actually make news. He has inherited a Gilead whose next big idea, treating the liver disease NASH, has run into serious setbacks this year. The company’s once-massive hepatitis C business has ceased to grow, and its embrace of oncology has moved in fits and starts at great expense. And people are losing their jobs.

All of that makes Thursday’s call, which starts after the market close, into both an introduction for O’Day and a state-of-the-company address for Gilead. When the time comes, you can stream it here.